4 completed, 1 withdrawn. 5 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 4, Withdrawn 1 |
Follow BRCA2 Mutation Carrier: new trials by email Literature Review of BRCA2 Mutation Carrier trials Research Report on BRCA2 Mutation Carrier
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer counseling intervention, behavioral dietary intervention, exercise intervention - Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia | Not applicable | Completed | University of Washington | 17 | 2013-10-01 | 2016-01-20 |
| S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer cholecalciferol, placebo - brca1 Mutation Carrier, brca2 Mutation Carrier | Not applicable | Completed | SWOG Cancer Research Network | 208 | 2011-11-01 | 2017-11-24 |
| Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer soy isoflavones, placebo, questionnaire administration - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Not applicable | Completed | University of Southern California | 110 | 2010-07-01 | 2023-11-18 |
| Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries fenretinide - brca1 Mutation Carrier, brca2 Mutation Carrier | Not applicable | Completed | University of Arizona | 40 | 2004-10-01 | 2010-03-24 |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy celecoxib, oophorectomy - brca1 Mutation Carrier, brca2 Mutation Carrier | Not applicable | Withdrawn | University of Alabama at Birmingham | 2002-06-01 | 2013-08-22 |
Breast Carcinoma In Situ (3) · Carcinoma, Intraductal, Noninfiltrating (3) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2) · Ovarian Neoplasms (2)
Carcinoma (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (3) · Breast Diseases (3) · Carcinoma in Situ (3) · Neoplasms, Ductal, Lobular, and Medullary (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2)
Biopsy (1) · Celecoxib (1) · Cholecalciferol (1) · Counseling (1) · Fenretinide (1) · Immunohistochemistry (1) · Magnetic Resonance Spectroscopy (1) · Ovariectomy (1) · Soybean Proteins (1)
SWOG Cancer Research Network (1) · University of Alabama at Birmingham (1) · University of Arizona (1) · University of Southern California (1) · University of Washington (1)
United States (5)
Anna Wu (1) · Edward E. Partridge, MD (1) · Katherine D. Crew, MD, MS (1) · Kerryn Reding (1) · Molly A. Brewer, MD, DVM, MS (1)
P30CA015704 (1), P30CA016672 (1), R00NR012232 (1), U10CA037429 (1)